Test Results Bolster Spraying of Stem Cells on Wounds, Burns for Rapid Healing

RenovaCare Inc. has unveiled positive spray test results that indicate its SkinGun technology achieves exceptionally-uniform distribution of fluids with 200 times greater coverage than conventional methods. These outcomes are especially promising to scientists developing patented RenovaCare CellMist and SkinGun technologies for spraying fluids with a patient’s own stem cells onto burns and wounds for rapid scar-free healing.
 
“These results mark important technical milestones in our pathway to spraying patient wounds with their own stem cells to promote fast and natural skin repair,” said Thomas Bold, president and CEO of RenovaCare. “Data from ongoing preclinical work supports our long-held conviction that our SkinGun technology is superior to standard methods for delivering fluids and stem cells to target sites, achieving excellent coverage while being extremely gentle to the cells.”
 
In addition to the tests showing high distribution and concentration patterns, the SkinGun recently demonstrated the ability to spray powerful yet delicate skin stem cells ultra-gently. Scientists reported 97.3 percent cell viability after SkinGun spraying. Cell viability is essential to regenerating skin for burns, wounds, and cosmetic applications.
 
Specifically, scientists at one of the world’s largest university hospitals, Berlin-Brandenburg Center for Regenerative Therapies (BCRT), a translational research center at Charité–Universitätsmedizin Berlin (Germany), sprayed human skin stem cells using the RenovaCare SkinGun. Among the technical aims of the study was the evaluation of several factors important to the regeneration of human skin, including cell yield, viability, metabolic activity, and cell growth.
 
Positive results were reported from experiments related to each of these investigations, and cell growth was comparable to pipetting, the industry’s widely accepted ‘gold-standard’ for the deposition of cells.
 
In these latest tests, scientists repeatedly sprayed fluids at various airflow rates using the RenovaCare SkinGun, resulting in 200-times more droplets than conventional ‘syringe deposition.’ For example, in an 8-centimeter diameter surface area, the SkinGun delivered more than 20,000 evenly distributed droplets versus only 91 droplets by conventional needle and syringe methods.
 
Scientists evaluated droplet size, distribution, and density alongside spray velocity and fluid viscosity in experiments conducted at Stem cell Systems GmbH (Berlin, Germany). Additional testing of the SkinGun remains ongoing.
 
The RenovaCare medical-grade spray device gently sprays a well-dispersed mist of wound care and/or irrigation fluids using a patented liquid-into-air stream system. The device targets the estimated $45 billion plus wound care market in the United States.
 
RenovaCare products are currently in development. They are not available for sale in the United States.
 
RenovaCare is developing autologous (self-donated) stem cell therapies for the regeneration of human organs, and novel medical grade liquid sprayer devices.
 
The company’s pipeline products under development target the skin. The RenovaCare CellMist System will use the patented SkinGun to spray a liquid suspension of a patient’s stem cells—the CellMist Solution—onto wounds. RenovaCare is developing its CellMist System as a new alternative for patients suffering from burns, chronic and acute wounds, and scars. In the United States, this $45 billion market is greater than the spending on high-blood pressure management, cholesterol treatments, and back pain therapeutics. In addition to the SkinGun, the New York, N.Y.-based company is developing a medical-grade sprayer that uses a liquid-into-air stream system to disperse a gentle spray of wound care and/or irrigation fluids over a wound area.